Plasma derived versus biotechnological manufactured medicine

The research on alternatives for plasma products, whether biotechnological developed medicinal products or recombinant alternatives to plasma products, with the development of recombinant factor viii started at the end of the 1980s. there was considerable interest in the possibility of producing a ‘synthetic’ form of factor viii and factor ix in view of the high rate of transmission of blood-borne viruses by plasma derived factor concentrates in the 1970s and early 1980s,.